GO:0043086 negative regulation of catalytic activity: Enzyme Control Mechanisms, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0043086 describes any biological process that stops or reduces the activity of an enzyme, encompassing direct inhibition, post-translational modification, and sequestration of catalytic subunits [1,4,7].
• Negative regulation of catalytic activity is essential for preventing uncontrolled signaling, DNA degradation, and cell death, as shown for TREX1, caspase 3-cleaved PAK2, and p34cdc2 kinase [1,4,7].
• Key molecular mechanisms include phosphorylation/dephosphorylation, competitive or allosteric inhibition, and co-assembly into inactive complexes [4,7,8].
• Dysregulation of this process contributes to cancer, autoimmune disease, and infection, with examples including EZH2 in triple-negative breast cancer and A20 in NF-κB signaling [2,5].
• CRISPR knockout, point-mutation, knock-in, and overexpression models enable precise interrogation of negative regulators of catalytic activity [2,5,6].
• Studying GO:0043086 requires integrated methods such as enzymatic assays, phosphoproteomics, and structural biology to resolve dynamic inhibition events [3,6,8].
Description
Negative regulation of catalytic activity (GO:0043086) is a fundamental biological process that ensures enzymes are active only when and where needed. It encompasses any mechanism that stops or reduces enzyme activity, including direct binding of inhibitors, post-translational modifications, and changes in subunit composition [1,4,7]. This process is critical for maintaining cellular homeostasis, preventing aberrant signaling, and coordinating complex pathways such as DNA sensing and cell cycle progression [1,7]. Researchers study GO:0043086 to understand how cells avoid runaway catalysis, how pathogens subvert host enzymes, and how mutations in regulatory nodes drive disease [2,5,6]. The term is particularly relevant in cancer biology, immunology, and neurobiology, where fine-tuning of enzyme activity determines cell fate [2,4,5].
negative regulation of catalytic activity At A Glance
| GO ID | GO:0043086 |
|---|---|
| GO term | negative regulation of catalytic activity |
| Ontology | biological_process |
| Synonym | down regulation of enzyme activity; down-regulation of enzyme activity; downregulation of enzyme activity; down regulation of metalloenzyme activity; down-regulation of metalloenzyme activity; downregulation of metalloenzyme activity; inhibition of enzyme activity; inhibition of metalloenzyme activity; negative regulation of enzyme activity; negative regulation of metalloenzyme activity |
| Major function | Stops or reduces the activity of an enzyme, preventing uncontrolled catalysis and maintaining pathway balance |
| Biological context | Cell cycle control, DNA damage response, immune signaling, and pathogen-host interactions |
| Regulatory modes | Phosphorylation, dephosphorylation, allosteric inhibition, competitive inhibition, subunit sequestration, and co-assembly |
| Disease relevance | Cancer, autoimmune disorders, and infectious diseases |
| Experimental approaches | Enzymatic assays, CRISPR knockout/knock-in, phosphoproteomics, and structural biology |
What Is GO:0043086?
GO:0043086, negative regulation of catalytic activity, is defined as any process that stops or reduces the activity of an enzyme. This includes direct inhibition of catalytic function, down-regulation of metalloenzyme activity, and inhibition of enzyme activity through diverse molecular mechanisms. It is a biological process that can act on a single enzyme or a multi-subunit complex, and it is distinct from regulation of gene expression because it targets the enzyme protein itself rather than its synthesis or degradation.
Why Is negative regulation of catalytic activity Important in Cell Biology?
Negative regulation of catalytic activity is essential for cellular life because it prevents enzymes from acting indiscriminately, which would otherwise lead to futile cycles, DNA damage, or uncontrolled proliferation. For example, cGAS phase separation inhibits TREX1-mediated DNA degradation to enhance cytosolic DNA sensing, illustrating how negative regulation of a nuclease is critical for immune detection of pathogens. Similarly, protein phosphatase 1 negatively regulates caspase 3-cleaved PAK2 activity, a process that controls apoptotic signaling. In cancer, inhibition of EZH2 catalytic activity selectively targets a metastatic subpopulation in triple-negative breast cancer, demonstrating that disrupting negative regulation can have therapeutic benefit. Thus, understanding GO:0043086 provides mechanistic insights into disease and identifies targets for intervention.
• Prevents uncontrolled enzymatic activity that could damage DNA or proteins.
• Controls cell cycle progression through regulation of p34cdc2 kinase.
• Modulates immune signaling by regulating NF-κB pathway components such as A20.
• Influences cancer progression and metastasis, as shown for EZH2 in triple-negative breast cancer.
• Regulates bacterial virulence factors, such as Shigella Spa47 ATPase.
• Affects peptide fibril catalytic activity through co-assembly.
• Provides targets for therapeutic intervention in autoimmune and inflammatory diseases.
• Enables precise control of apoptosis via caspase-cleaved PAK2 regulation.
• Impacts metalloenzyme function, with synonyms reflecting this specificity.
• Is essential for understanding host-pathogen interactions and infectious disease.
What Happens During negative regulation of catalytic activity?
Initiation by regulatory signals
In simple terms: A signal tells the cell to shut down or slow an enzyme.
Negative regulation of catalytic activity often begins with a cellular signal, such as DNA damage, cytokine stimulation, or cell cycle checkpoint activation. For instance, cGAS phase separation acts as a signal that inhibits TREX1-mediated DNA degradation, enhancing cytosolic DNA sensing. Similarly, phosphorylation events can trigger the negative regulation of p34cdc2 protein kinase activity by modulating its interaction with cyclin binding partners. These initiating signals ensure that enzyme inhibition is context-dependent and reversible.
Direct inhibition by binding partners
In simple terms: An inhibitor molecule binds to the enzyme and blocks its active site or changes its shape.
Direct binding of inhibitory proteins or small molecules can stop or reduce enzyme activity. A20 mediates negative regulation of the canonical NF-κB signaling pathway by acting as an inhibitor of upstream kinases, thereby preventing excessive inflammatory responses. In bacterial systems, a native C-terminal product of Spa33 differentially regulates Shigella Spa47 ATPase activity, illustrating direct inhibition of a virulence-associated enzyme. Such binding events are often reversible and can be competitive or allosteric.
Post-translational modification
In simple terms: Adding or removing chemical tags like phosphate groups can switch an enzyme off.
Phosphorylation and dephosphorylation are major mechanisms for negative regulation of catalytic activity. Protein phosphatase 1 negatively regulates caspase 3-cleaved PAK2 activity by removing phosphate groups, thereby controlling apoptotic signaling. Conversely, phosphorylation of p34cdc2 kinase can inhibit its activity depending on the site and context. These modifications provide rapid and dynamic control over enzyme function.
Sequestration and co-assembly
In simple terms: Enzymes can be trapped in inactive complexes or fibrils, preventing them from working.
Enzymes can be negatively regulated by sequestration into inactive complexes or by co-assembly with other molecules. Co-assemblies regulate the catalytic activity of peptide fibrils, demonstrating that higher-order structures can modulate enzyme function. Similarly, phase separation of cGAS inhibits TREX1, effectively sequestering the nuclease away from its substrate. These mechanisms highlight the role of spatial organization in negative regulation.
Feedback and pathway integration
In simple terms: The product of a reaction can turn off the enzyme that made it, creating a self-limiting loop.
Negative regulation of catalytic activity is often integrated into feedback loops. For example, A20-mediated inhibition of NF-κB signaling is part of a negative feedback circuit that prevents sustained inflammation. In the cell cycle, p34cdc2 kinase activity is regulated by phosphorylation and cyclin binding to ensure orderly progression. Such feedback ensures that enzyme activity is tightly coupled to cellular needs.
Key Genes Involved in GO:0043086 negative regulation of catalytic activity
The following genes and proteins are experimentally validated participants in negative regulation of catalytic activity (GO:0043086), based on the cited literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| TREX1 | DNA exonuclease inhibited by cGAS phase separation | Cytosolic DNA sensing and autoimmune disease |
| EZH2 | Histone methyltransferase; catalytic inhibition targets metastatic cells | Triple-negative breast cancer therapy |
| ADAM33 | Metalloprotease with regulated catalytic activity | Asthma and airway remodeling |
| PAK2 | Kinase negatively regulated by protein phosphatase 1 after caspase cleavage | Apoptosis and cytoskeletal dynamics |
| A20 (TNFAIP3) | Inhibitor of NF-κB signaling via negative regulation of kinases | Autoimmunity and lymphoma |
| Spa47 | ATPase negatively regulated by Spa33 C-terminal product | Shigella virulence and bacterial secretion |
| p34cdc2 (CDK1) | Cell cycle kinase regulated by phosphorylation and cyclin binding | Cell cycle control and cancer |
| Peptide fibrils | Catalytic activity modulated by co-assembly | Biomaterials and amyloid biology |
| Protein phosphatase 1 | Dephosphorylates and inactivates PAK2 | Apoptosis and signal transduction |
| Cyclin | Binding partner that regulates p34cdc2 kinase activity | Cell cycle progression |
| Spa33 | Produces C-terminal product that inhibits Spa47 ATPase | Bacterial pathogenesis |
| cGAS | Phase separates to inhibit TREX1 | Innate immunity and DNA sensing |
| NF-κB pathway kinases | Negatively regulated by A20 | Inflammation and immune homeostasis |
| EZH2 complex components | Modulate EZH2 catalytic activity | Epigenetic therapy |
| ADAM33 prodomain | Regulates metalloprotease activity | Asthma and protease biology |
| Caspase 3 | Cleaves PAK2 to generate a form regulated by PP1 | Apoptosis |
| Metalloenzymes | Subject to negative regulation of metalloenzyme activity | Broad enzymatic regulation |
How Is negative regulation of catalytic activity Regulated?
Negative regulation of catalytic activity is itself regulated at multiple levels. For example, the cGAS-TREX1 axis is controlled by phase separation, which acts as a switch to inhibit TREX1 during cytosolic DNA sensing. In the NF-κB pathway, A20 expression is induced by NF-κB activation, creating a negative feedback loop that limits the duration of signaling. Cell cycle-dependent phosphorylation of p34cdc2 is regulated by cyclin binding and opposing phosphatases, ensuring timely inactivation. Additionally, co-assembly of peptide fibrils can be modulated by environmental factors, altering catalytic activity. These regulatory layers allow cells to fine-tune enzyme inhibition in response to changing conditions.
negative regulation of catalytic activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| EZH2 | Triple-negative breast cancer metastasis | Knockout or point-mutation of catalytic domain in cancer cell lines |
| TREX1 | Autoimmune disease and DNA sensing | Knock-in of phase-separation-deficient cGAS or TREX1 mutants |
| A20 (TNFAIP3) | Lymphoma and inflammatory disorders | Knockout in immune cells to study NF-κB regulation |
| Spa47 | Shigella infection | Bacterial knockout or point mutation of ATPase domain |
| ADAM33 | Asthma and airway remodeling | Overexpression or knockout in airway smooth muscle cells |
Cancer
Dysregulation of negative regulation of catalytic activity contributes to cancer. Inhibition of EZH2 catalytic activity selectively targets a metastatic subpopulation in triple-negative breast cancer, suggesting that EZH2 overactivity drives metastasis and that its negative regulation is a therapeutic strategy. Similarly, loss of A20-mediated negative regulation of NF-κB signaling is associated with lymphomas and autoimmune disorders. Targeting negative regulators of catalytic activity can therefore restore control over proliferative signaling.
Autoimmune and inflammatory diseases
Defects in negative regulation of catalytic activity can lead to autoimmunity. For instance, TREX1 is negatively regulated by cGAS phase separation to prevent excessive DNA degradation; when this regulation is impaired, cytosolic DNA accumulates and triggers autoimmune responses. A20 negatively regulates NF-κB signaling, and its dysfunction is linked to inflammatory diseases. These examples highlight the importance of enzyme inhibition in immune homeostasis.
Infectious diseases
Pathogens exploit or subvert negative regulation of catalytic activity. Shigella Spa47 ATPase is negatively regulated by a native C-terminal product of Spa33, which modulates bacterial secretion and virulence. Understanding these regulatory mechanisms can inform the development of anti-virulence therapies.
Asthma and airway disease
ADAM33 is a metalloprotease whose catalytic activity is subject to negative regulation, and its dysregulation has been implicated in asthma pathogenesis. Modulating ADAM33 activity may offer therapeutic avenues for airway remodeling.
From negative regulation of catalytic activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of a negative regulator increase enzyme activity? | CRISPR knockout of the regulator gene [2,5] |
| Does a specific phosphorylation site control enzyme inhibition? | Point mutation of the phospho-acceptor site [4,7] |
| Does a disease-associated mutation disrupt negative regulation? | Knock-in of the patient mutation |
| Where and when does the regulator interact with the enzyme? | Tagged knock-in for imaging or proximity labeling [1,6] |
| Does overexpression of the regulator suppress enzyme activity? | Overexpression of the regulator in cell lines |
| Can co-assembly modulate catalytic activity? | Engineered peptide fibrils with controlled composition |
How to Study the negative regulation of catalytic activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Enzymatic activity assay | Catalytic rate of the enzyme | Quantifying inhibition by regulators [3,6] |
| Phosphoproteomics | Changes in protein phosphorylation | Identifying regulatory phosphorylation sites [4,7] |
| Western blot | Protein levels and modification states | Validating knockout or knock-in [2,5] |
| Fluorescence microscopy | Subcellular localization and phase separation | Studying sequestration mechanisms |
| Structural biology (cryo-EM, NMR) | Three-dimensional structure of complexes | Visualizing inhibitor binding |
| CRISPR knockout screen | Genes required for enzyme regulation | Discovering negative regulators [2,5] |
| Co-immunoprecipitation | Protein-protein interactions | Detecting regulator-enzyme complexes [4,6] |
| ATPase assay | ATP hydrolysis rate | Measuring inhibition of ATPases |
Enzymatic activity assays
Direct measurement of enzyme activity using fluorogenic or luminescent substrates is the gold standard for studying negative regulation of catalytic activity. For example, ADAM33 catalytic activity was characterized using peptide substrates, and Spa47 ATPase activity was measured by ATP hydrolysis. These assays allow quantification of inhibition in response to regulatory proteins or modifications.
Phosphoproteomics and western blotting
Phosphorylation is a key mechanism of negative regulation. Protein phosphatase 1-mediated dephosphorylation of PAK2 was demonstrated by phospho-specific antibodies and kinase assays. Similarly, p34cdc2 regulation by phosphorylation was studied using metabolic labeling and immunoprecipitation. Phosphoproteomics can identify global changes in enzyme phosphorylation upon regulatory signals.
Structural biology and biophysics
Understanding how inhibitors bind or how co-assembly alters catalytic activity requires structural approaches. Co-assemblies regulating peptide fibril activity were studied using spectroscopy and microscopy. Phase separation of cGAS was visualized by fluorescence microscopy. These methods reveal the physical basis of negative regulation.
CRISPR-based genetic screens
Genome-wide CRISPR knockout screens can identify negative regulators of a given enzyme. For instance, inhibition of EZH2 catalytic activity was studied using CRISPR knockout of EZH2 in breast cancer cells. A20-mediated negative regulation of NF-κB was dissected using knockout models. Such screens are powerful for discovering new regulators.
How CRISPR Can Be Used to Study GO:0043086 negative regulation of catalytic activity
Knockout
CRISPR knockout of a negative regulator can lead to constitutive enzyme activation, revealing its role in pathway control. For example, knockout of A20 results in hyperactive NF-κB signaling. Knockout of EZH2 in triple-negative breast cancer cells reduces metastatic potential, demonstrating the importance of its catalytic activity. Knockout models are essential for loss-of-function studies of GO:0043086.
Point Mutation
Point mutations can abrogate specific regulatory modifications, such as phosphorylation sites. Mutating the phospho-acceptor site on p34cdc2 prevents its negative regulation by phosphorylation, leading to cell cycle defects. Similarly, point mutations in the catalytic domain of EZH2 can render it insensitive to inhibitors. These models allow precise dissection of regulatory mechanisms.
Knock-in
Knock-in of disease-associated mutations or tagged versions of regulators enables study of their function in a physiological context. For instance, knock-in of a phase-separation-deficient cGAS mutant would disrupt TREX1 inhibition. Tagged knock-in of Spa33 allows tracking of its C-terminal product and its effect on Spa47. These models are valuable for understanding dynamic regulation.
Overexpression
Overexpression of a negative regulator can suppress enzyme activity and phenocopy inhibition. Overexpression of protein phosphatase 1 reduces PAK2 activity and affects apoptosis. Overexpression of A20 inhibits NF-κB signaling. Such models are useful for gain-of-function studies and for validating therapeutic targets.
How EDITGENE Supports negative regulation of catalytic activity Research
Researchers studying negative regulation of catalytic activity-related genes often need to determine whether a candidate gene is causally involved in enzyme inhibition, and CRISPR-based models provide the most direct approach. EDITGENE offers a comprehensive suite of services to generate and characterize such models.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of catalytic activity research.
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| NOTCH1 Knockout HEK293 Cell Line | EDJ-KQ435 | Human | 4851 | Details Get a Quote |
| NES Knockout HEK293 Cell Line | EDJ-KQ3620 | Human | 10763 | Details Get a Quote |
| APBA3 Knockout HEK293 Cell Line | EDJ-KQ6633 | Human | 9546 | Details Get a Quote |
| NOSIP Knockout HEK293 Cell Line | EDJ-KQ10901 | Human | 51070 | Details Get a Quote |
| CCAR2 Knockout HEK293 Cell Line | EDJ-KQ11949 | Human | 57805 | Details Get a Quote |
| CAND1 Knockout HEK293 Cell Line | EDJ-KQ12720 | Human | 55832 | Details Get a Quote |
| TMBIM1 Knockout HEK293 Cell Line | EDJ-KQ15750 | Human | 64114 | Details Get a Quote |
| NOTCH1 Knockout A-549 Cell Line | EDJ-KQ18001 | Human | 4851 | Details Get a Quote |
| NES Knockout HCT 116 Cell Line | EDJ-KQ24180 | Human | 10763 | Details Get a Quote |
| NOTCH1 Knockout HeLa Cell Line | EDJ-KQ18299 | Human | 4851 | Details Get a Quote |
| NOTCH1 Knockout HCT 116 Cell Line | EDJ-KQ18733 | Human | 4851 | Details Get a Quote |
| NES Knockout A-549 Cell Line | EDJ-KQ25556 | Human | 10763 | Details Get a Quote |
| NES Knockout HeLa Cell Line | EDJ-KQ25558 | Human | 10763 | Details Get a Quote |
| APBA3 Knockout A-549 Cell Line | EDJ-KQ30887 | Human | 9546 | Details Get a Quote |
| APBA3 Knockout HCT 116 Cell Line | EDJ-KQ30888 | Human | 9546 | Details Get a Quote |
- 1
- 2
- Next Page »
Frequently Asked Questions About negative regulation of catalytic activity
What is negative regulation of catalytic activity?
Negative regulation of catalytic activity (GO:0043086) is any biological process that stops or reduces the activity of an enzyme, such as inhibition by binding partners, phosphorylation, or sequestration [1,4,7].
What genes are involved in negative regulation of catalytic activity?
Key genes include TREX1, EZH2, PAK2, A20, Spa47, p34cdc2, and protein phosphatase 1, among others [1,2,4,5,6,7].
How is enzyme activity negatively regulated?
Enzymes can be negatively regulated by direct inhibitor binding, post-translational modifications like phosphorylation, sequestration into inactive complexes, or co-assembly [1,4,5,7,8].
What diseases are associated with defects in negative regulation of catalytic activity?
Defects are linked to cancer, autoimmune diseases, inflammatory disorders, and infectious diseases [1,2,5,6].
What is the GO ID for negative regulation of catalytic activity?
The GO ID is GO:0043086.
How can CRISPR be used to study negative regulation of catalytic activity?
CRISPR knockout, point mutation, knock-in, and overexpression models allow researchers to test the function of negative regulators and their impact on enzyme activity [2,4,5,6].
What are examples of negative regulation of catalytic activity in cancer?
Inhibition of EZH2 catalytic activity targets metastatic triple-negative breast cancer cells, and A20 negatively regulates NF-κB signaling to suppress lymphoma [2,5].
What methods are used to measure negative regulation of catalytic activity?
Common methods include enzymatic activity assays, phosphoproteomics, western blotting, fluorescence microscopy, and structural biology [1,3,4,6,8].
Is negative regulation of catalytic activity reversible?
Yes, many forms of negative regulation, such as phosphorylation and inhibitor binding, are reversible and dynamic [4,7].
What is the difference between negative regulation of catalytic activity and enzyme inhibition?
Negative regulation of catalytic activity is a broader biological process that includes any mechanism reducing enzyme activity, while enzyme inhibition often refers to direct binding of an inhibitor [1,5].
Conclusion
Negative regulation of catalytic activity (GO:0043086) is a central mechanism for controlling enzyme function in health and disease. From DNA sensing to cell cycle control and cancer metastasis, the precise inhibition of enzymes ensures cellular fidelity. Understanding these processes requires integrated genetic, biochemical, and structural approaches. EDITGENE provides the CRISPR tools and expertise to dissect these regulatory networks and accelerate therapeutic discovery.
References
- 1. Zhou W et al.. 2021. cGAS phase separation inhibits TREX1-mediated DNA degradation and enhances cytosolic DNA sensing.. Mol Cell 81(4):739-755.e7 PMID: 33606975
- 2. Yomtoubian S et al.. 2020. Inhibition of EZH2 Catalytic Activity Selectively Targets a Metastatic Subpopulation in Triple-Negative Breast Cancer.. Cell Rep 30(3):755-770.e6 PMID: 31968251
- 3. Zou J et al.. 2004. Catalytic activity of human ADAM33.. J Biol Chem 279(11):9818-30 PMID: 14676211
- 4. Wang J et al.. 2008. Negative regulation of caspase 3-cleaved PAK2 activity by protein phosphatase 1.. Sci China C Life Sci 51(1):1-11 PMID: 18176785
- 5. Pujari R et al.. 2013. A20-mediated negative regulation of canonical NF-κB signaling pathway.. Immunol Res 57(1-3):166-71 PMID: 24242761
- 6. Case HB et al.. 2023. Differential regulation of Shigella Spa47 ATPase activity by a native C-terminal product of Spa33.. Front Cell Infect Microbiol 13:1183211 PMID: 37389216
- 7. Nigg EA et al.. 1992. Regulation of p34cdc2 protein kinase activity by phosphorylation and cyclin binding.. Ciba Found Symp 170:72-84; discussion 84-96 PMID: 1483352
- 8. Lahu A et al.. 2026. Co-Assemblies Regulate the Catalytic Activity of Peptide Fibrils.. Angew Chem Int Ed Engl 65(2):e11165 PMID: 41346087
